Learn More >

Ministry Status: Activation Status

Patient Evidence Submissions

Drug Review Schedule

The Ontario Public Drug Program is currently accepting submissions of patient evidence on the following drug products which will undergo review by the Committee to Evaluate Drugs within the next 12 months.

Drug products on this list include new chemical entities, new combination products and existing drug products with a new indication recently approved by Health Canada. At this time, drug products that are line extensions (such as additional strengths and new dosage forms) and drug products that are undergoing reconsideration (second review, etc.) will not be considered for patient submissions. The Ministry will re-evaluate this once additional experience on the process is gained.

For drug products accepted for Rapid Review process, best efforts will be made to provide maximal time for patient submissions. However, in view of the intent of Rapid Review, the review of a drug product accepted for Rapid Review will not be held if only to include presentation of patient submissions.

Registered patient groups are invited to provide patient evidence on any of the drugs listed below.

All submissions must be received by 5:00pm of the deadline date.


Generic Name Brand Name Manufacturer Indication / Type of Review Deadline for Patient Submissions
Nivolumab Opdivo Bristol-Myers Squibb Canada Hodgkin lymphoma (after failure of autologous stem cell transplant) (pCODR) March 21, 2018
Brentuximab vedotin Adcetris Seattle Genetics, Inc. Hodgkin lymphoma (after autologous stem cell transplant and at high risk of relapse or progression) (pCODR) February 21, 2018
Buprenorphine/naloxone Suboxone Indivior Canada Ltd. Substitution treatment for opioid dependence (request for funding of new tablet strengths) February 21, 2018
Guselkumab Tremfya Janssen Inc. Psoriasis, plaque, moderate to severe (CDR) February 21, 2018
Tocilizumab Actemra Hoffmann-La Roche Limited Giant cell arteritis (CDR) February 21, 2018
Regorafenib Stivarga Bayer Inc. Hepatocellular carcinoma, unresectable (after treatment with sorafenib) (pCODR) February 21, 2018
Guanfacine Intuniv XR Shire Pharma Canada ULC Attention deficit hyperactivity disorder in children/adolescents aged 6-17 years (in combination with psychostimulants or as monotherapy in those unable to tolerate psychostimulants) January 31, 2018
Pembrolizumab Keytruda Merck Canada Inc. Urothelial carcinoma, metastatic (after platinum-containing chemotherapy) (pCODR) January 24, 2018
Panitumumab Vectibix Amgen Canada Inc. Left-sided metastatic colorectal cancer (first-line, in combination with chemotherapy) (pCODR) January 24, 2018
Vosevi Gilead Sciences Canada, Inc. Hepatitis C, chronic (CDR) January 24, 2018
Glecaprevir/pibrentasvir Maviret AbbVie Corporation Hepatitis C, chronic (CDR) January 17, 2018
Fulvestrant Faslodex AstraZeneca Canada Inc. Breast cancer, locally advanced or metastatic, HER2-negative (no prior endocrine therapy) (pCODR) January 17, 2018
Midostaurin Rydapt Novartis Pharmaceuticals Canada Inc. Acute myeloid leukemia, FLT3-mutated, newly diagnosed (in combination with standard chemotherapy) (pCODR) December 20, 2017
Apixaban Eliquis Bristol-Myers Squibb Canada Venous thromboembolism (ministry-initiated review of Limited Use criteria for potential expansion beyond 6-month duration) December 18, 2017
Pentoxifylline Pentoxifylline SR AA Pharma Inc. Venous ulcers (clinician-initiated submission) December 18, 2017
Rivaroxaban Xarelto Bayer Inc. Venous thromboembolism (ministry-initiated review of Limited Use criteria for potential expansion beyond 6-month duration) December 18, 2017

See also:

Image:Pdf icon.gif To view PDF format files, you need to have Adobe Acrobat® Reader installed on your computer.
You can download this free software from the Adobe Web site.

For More Information

Call ServiceOntario, Infoline at:
1-866-532-3161 (Toll-free)
In Toronto, (416) 314-5518
TTY 1-800-387-5559.
In Toronto, TTY 416-327-4282
Hours of operation : Monday to Friday, 8:30am - 5:00pm